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Abstract Human CD38 is the mammalian prototype
of a family of phylogenetically conserved proteins
which share structural similarities and enzymatic
activities involved in the production of an intracellular
second messenger with calcium mobilizing effects.
Engagement of CD38 by agonistic monoclonal anti-
bodies and the CD31 ligand initiates a cytoplasmic
signaling cascade involving tyrosine phosphorylation
of the proto-oncogene c-cbl and of the extracellular
regulated kinase 1 of 2 complex. Further requirements
for signal transduction include a privileged localization
within the cholesterol-rich areas of the plasma mem-
brane and physical association with specialized surface
receptors. CD38-mediated signals are crucial in het-
erotypic cell adhesion and migration as well as in the
activation of proliferation/survival programs by normal
and neoplastic cells. Here we review the most recent
literature on this complex topic and attempt to
formulate a single model reconciling the enzymatic
and receptorial activities of CD38.
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Abbreviations
BM bone marrow
cADPR cyclic ADP ribose
IP3 inositol triphosphate
ERK1/2 extracellular regulated kinase 1/2
mAbs monoclonal antibodies
NAD nicotinamide adenine dinucleotide
Introduction
The concept of cell surface molecules with a catalyt-
ically active site in the extracellular environment was
lastly brilliantly analyzed in a dedicated issue of
Immunological Reviews edited by Goding and Howard
[1]. At the time it was becoming clear that ectoen-
zymes could no longer be considered an oddity in
leukocyte biology; on the contrary, it was seen that
õ3.5% of the molecules expressed on the surface of
human and murine cells shared such characteristics.
This ﬁnding galvanized the attention and interest of
basic scientists and, later, of clinical scientists as well.
Nucleotide-metabolizing ectoenzymes constitute a
family within this larger family and are represented by
a set of molecules involved in the catabolism and
scavenging of extracellular nucleotides. This process
results in the synthesis of compounds that play a
critical role in cell homeostasis and metabolism,
suggesting that the physiological role of this complex
family goes beyond the simple recycling of nucleotides.
One of the characteristics initially thought to be
shared by several, even though not all, nucleotide-
metabolizing ectoenzymes was the ability to work in
an environment where the substrate was generally
present only in trace amounts and where the ﬁnal
product would be used prevalently inside the cell [2].
This initial view of enzymes working in an anti-
economical environment was later reﬁned thanks also
Purinergic Signalling (2006) 2:431–441
DOI 10.1007/s11302-006-9002-6
S. Deaglio: F. Malavasi ())
Laboratory of Immunogenetics, Department of Genetics,
Biology and Biochemistry, and Research Center
on Experimental Medicine,
University of Torino Medical School,
via Santena, 19, 10126 Torino, Italy
e-mail: fabio.malavasi@unito.itto the more sophisticated experimental approaches
conﬁrming that substrates and ﬁnal products are not so
topologically conﬁned [3].
The majority of these molecules, identiﬁed using
the grid of the CD International Workshop on Dif-
ferentiation Antigens and considered to be orphan
molecules, found initial clinical applications as disease
markers. Indeed, CD38 is still considered an Facti-
vation marker,_ useful in the diagnosis of leukemias
and myelomas [4], while CD39 was initially deﬁned as
a marker of EBV infection [5]. The same fate was
shared by CD26 [6] and CD10/CALLA [7], probably
the most commonly used clinical markers, as well as
PC-1 [8], one of the ﬁrst reliable markers of human
plasma cells.
This review will focus on the CD38/CD157 family of
ADP ribosyl cyclases and their relevance in physiology
and human pathology.
CD38 and CD157: The early days
CD38 was identiﬁed during detailed analysis of the cell
surface by means of monoclonal antibodies (mAbs) as
carried out by EL Reinherz and SF Schlossman during
their pioneer search for molecules acting as T-cell
receptors and as transducers of the signals elicited by
the encounter with the speciﬁc antigen [9]. The upshot
of that approach was the deﬁnition of a vast array of
molecules, including some involved in the economy of
discrete subsets of cells (CD4 and CD8), some playing
the more general role of metabolic regulators (CD71/
TFR-1) and several others, such as CD38, that served
as markers for the study of thymocytes, activated T
cells and selected tissues [10, 11].
Our interest in investigating human CD38 was
sparked by the distribution of the molecule, which
ranged from discrete expression during thymic differ-
entiation to an extremely limited presence during the
normal physiological life of a T cell. The molecule was
re-expressed at high density by T cells undergoing
activation and in selected leukemias [12]. In apparent
contrast to the simplistic view of CD38 an activation
marker was the ﬁnding that terminally differentiated
plasma cells and their pathological counter-parts
expressed the highest surface amount among human
cells.
Our analysis proceeded from the observation that
CD38, a 45 kD molecule, was initially reported as
being associated to a 12 kD single chain protein,
reminiscent of a family of HLA Class I-like molecules
known at that time as T6 (now CD1a) [13]. That view
was disconﬁrmed once we generated an extensive
panel of mAbs speciﬁc for the molecule, which
enabled us to perform an initial structural analysis
that ruled out the presence of b2-microglobulin.
Moreover, using a somatic cell genetics approach, the
gene coding for the structure was attributed to human
chromosome 4 (4p15, and thus outside the canonical
HLA supergene in chromosome 6) [14].
One of the mAbs in the panel used for the
characterization of human CD38 was found to induce
signals after binding to its target, a new and unforeseen
characteristic of mAbs [15]. An agonistic mAb is
usually a reagent with a very high afﬁnity for the
target, mimicking the interaction between ligand and
receptor. Using that agonistic mAb, CD38 was initially
reported as a surface molecule acting as a receptor
engagable by an unknown ligand [16]. While we were
busy analyzing the molecule from an immunological
perspective, CD38 unexpectedly became the focus of a
group of biochemists who were interested in the
regulation of calcium signaling through a pathway
independent from inositol triphosphate (IP3) [17].
H.C. Lee was able to identify cyclic ADP ribose
(cAPDR) as an intracellular second messenger and to
purify the enzyme responsible for its synthesis from
Aplysia californica, a mollusk separated from humans
by 80 million years. Surprisingly, the sequence of
soluble ADP ribosyl cyclase puriﬁed from Aplysia
proved strikingly similar to the leukocyte transmem-
brane antigen CD38.
The similarity in amino acid sequences between
Aplysia ADP ribosyl cyclase and the human lympho-
cyte antigen CD38 was timidly reported as a letter
which appeared in TIBS in December 1992 [18]. This
led to an explosion in interest by basic and clinical
scientists, astonished by the close similarity between
two such phylogenetically distant molecules. Human
and mouse CD38 were conﬁrmed to be ectoenzymes
[19, 20]. The underlying issue that had to be resolved
concerned the relationship between the molecule’s
receptorial and enzymatic activities: In other words,
are the signals implemented by CD38 ligation guided
by the intermediate or ﬁnal products synthesized by
CD38, or are the two functions independent?
The identiﬁcation of a second member of the CD38
family occurred during roughly the same years [21].
Bone marrow stromal antigen-1 (BST-1), later clus-
tered as CD157, was deﬁned as a stromal cell molecule
facilitating pre-B cell growth [22]. Its deduced amino
acid sequence exhibited 33% sequence homology with
CD38. Originally, BST-1/CD157 gene was mapped to
chromosome 14q32.3, where immunoglobulin heavy
432 Purinergic Signalling (2006) 2:431–441chain genes are clustered [22]. Further studies did not
conﬁrm that initial ﬁnding and instead mapped CD157
to chromosome 4p15, in close proximity to the CD38
gene [23].
This review is an attempt to present a uniﬁed
picture that encompasses both CD38 and CD157,
providing answers to several issues that have remained
unresolved after more than a decade of analysis.
CD38 as a signaling molecule
As mentioned, analysis using agonistic mAbs eventu-
ally led to characterization of the signaling pathway
controlled by CD38. Because the molecule is widely
expressed by lymphoid cells, the signaling events were
analyzed in detail in distinct lineages and during
discrete developmental stages. The emerging picture
is complex and non-univocal, but some common
threads seem to emerge.
a) CD38 engagement by agonistic mAbs is followed
by a signaling cascade typical of the canonical
receptors, including tyrosine phosphorylation of a
sequential number of intracellular enzymes, nucle-
ar events and more long-term effects dependent on
active protein synthesis. The individual steps of the
signaling pathway vary according to the model
studied; however, a common player in the CD38
pathway is the proto-oncogene c-cbl, which is
reported to be tyrosine phosphorylated in all the
cell models tested, including T, B, NK and myeloid
cells [24–28]. This observation suggests that CD38
may play a role in the ﬁne tuning of antigen
receptor signaling [29]. Moving further down, the
signal appears to be funneled through the ERK1/2
cross-point, at least in T and NK cells [28, 30].
b) An increase of the cytoplasmic levels of calcium
ions is also a common theme upon activation of
CD38. The calcium wave is typically low and slow
in rising as compared to the spikes obtained after
signaling through the antigen receptors in T and B
lymphocytes. Unlike the antigen receptors, a
CD38-induced calcium wave may last several
minutes before declining, indicating that the
molecular mechanisms responsible for calcium
mobilization might be different [27, 31, 32]. In
several instances, it was possible to determine
PLC-+ tyrosine phosphorylation upon CD38 cross-
linking, suggesting that the conventional IP3
pathway may account for calcium mobilization
[33, 34]; in other instances and mostly using
murine models, no PLC-+ activation could be
detected [35]. However, a direct contribution of
cADPR extracellularly produced by CD38 to the
signaling process cannot be convincingly ruled out,
as the deletion of the catalytically active site by
means of site-directed mutagenesis is followed by
a lack of binding by the available agonistic mAbs
[36, 37]. Moreover, activation of surface CD38 by
preincubation of cells with nicotinamide adenine
dinucleotide (NAD+) was found to lead to a dose-
dependent increase in cADPR, with no recordable
changes in the intracellular concentrations of
calcium ions [38, 39].
c) What ignites the signal? The lack of correlation
between CD38-mediated signals and the produc-
tion of cADPR, ADPR, and/or nicotinamide
prompted the search for alternative ligands capa-
ble of initiating the signaling process. The ﬁnding
that CD38 could modulate CD4
+/CD45RA
+ naı ¨ve
T lymphocyte [40] adhesion to endothelial cells
culminated with the identiﬁcation of a 130 kD
protein recognized by a soluble form of CD38 that
was used as a probe in a Western blot system [41].
This molecule turned out to be CD31/PECAM-1,
an Ig superfamily member mainly involved in the
modulation of leukocyte adhesion to the vessels
[42]. In subsequent years, most of the signals
recorded using agonistic mAbs were reproduced
by using the CD31 ligand. These included mobili-
zation of calcium signaling as well as more
structured events, such as proliferation and cyto-
kine induction [31, 43]. More recently, a similar
approach exploiting a soluble CD38-Ig recombi-
nant protein was used to identify novel ligands in
the murine system. As a result, a ligand of molec-
ular weight 130 kD, apparently different from
CD31, was detected on the surface of dendritic
cells [44],
d) The structural requirements for signaling are as
yet unclear. Of the various challenges facing
defenders of the receptor hypothesis, determining
how the signaling is initiated is perhaps the most
compelling. The role of the cytoplasmic tail is
controversial at this point. On the one hand, the
Lund group convincingly showed that the presence
of the intracellular residues of CD38 is irrelevant
for signals and enzymatic activities [38]. Moreover
it is generally accepted that the tail does not
contain signaling motifs. However, other studies
have determined – at least in T lymphocytes – a
direct association between the tail of CD38 and
the SH2 domain of the kinase lck [45].
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in critical areas of the plasma membrane in close
physical proximity with professional signaling
receptors [46], such as the T-cell receptor in T
lymphocytes [34], the B-cell receptor complex in B
cells [47], CD16 in NK cells [30], MHC Class II
and CD9 in monocytes [27, 48] and the CCR7
chemokine receptor, CD83 and CD11b in mature
dendritic cells [49]. Although these associations
are clearly visible using confocal microscopy, they
are lost when performing co-immunoprecipitation
experiments, suggesting either that the interaction
is weak or that there is an as yet unidentiﬁed third
party protein which acts as a bridge between CD38
and the other receptors. In line with the latter
hypothesis, recent papers have implied the exis-
tence of supramolecular complexes acting in
conjunction with multiple partners [48, 50]. These
complexes appear to reside within the cholesterol-
rich areas of the plasma membrane [51] and to be
dependent on their integrity [52]. The association
between CD38 and other signaling receptors was
deemed to have a functional nature, as implied by
the results of experiments with T, B and NK cell
line models genetically modiﬁed to lack functional
signaling receptors [30, 34, 53]. This hypothesis
was also conﬁrmed by using normal cells that lack
functional receptors [30].
e) The long-term events described as a consequence
of the interaction of CD38 with the CD31 ligand
and mimicked by agonistic mAbs vary according
to cell lineage and differentiation status. A
common theme in human T cells is the modulation
of a pattern of cytokines, including the classical
Th1 (IL-1, IL-6 and IFN-+) as well as the Th2
cytokines (IL-4 and IL-10) [54, 55]. The result is
implementation of a network of signals, which
ultimately rule the processes of proliferation,
survival and differentiation. This was recently
shown in tests of the receptor hypothesis using
chronic lymphocytic leukemia (CLL) as a model
[47]. CD38 was found to be expressed by a subset
of CLL cells characterized by shorter survival
times and shorter intervals prior to therapy [56–
58]. In these cells, CD38-mediated signals was
shown to lead to cell proliferation and to increase
the survival of the neoplastic clone by cooperating
with other survival receptors, including sema-
phorin CD100 [43]. The signals induced by the
agonistic mAb are fully mimicked after interaction
with the CD31 ligand, suggesting that this recep-
tor/ligand system may play a direct role in the
pathogenesis of CLL.
CD38 and CD157 as enzymes
As mentioned above, the extracellular domains of
CD38 and CD157 contain an enzymatic site that can
synthesize cADPR and nicotinic acid adenine dinucle-
otide phosphate (NAADP) from NAD
+ and NADP
+,
respectively [19, 59]. Thus, CD38 and CD157 are
ADP-ribosyl cyclases, a family of multifunctional
enzymes apparently ubiquitous in eukaryotic cells
[60]. CD38 and CD157 are the major enzymes with
ADP-ribosyl cyclase activity, although a non-CD38/
CD157 ADP-ribosyl cyclase has recently been
detected in brain tissue from CD38 knock-out (KO)
mice [61]. The most relevant product of the reaction is
cADPR, a universal second messenger with the ability
to control calcium levels in an IP3 independent way
[62]. cADPR – and thus ADP ribosyl cyclases – play a
key role in physiological processes, including cell
proliferation [63], muscle contraction [64, 65], stem
cell regeneration [66] and hormone secretion [67],
among the most relevant. Under normal physiologic
pH conditions, and unlike the Aplysia enzyme, CD38
is a very inefﬁcient cyclase, with cADPR representing
only 1%–3% of the ﬁnal products [19]. ADPR and
NAADP produced by CD38 [68] also cooperate in the
regulation and modulation of intracellular calcium:
Indeed, ADPR acts on plasma membrane LTRPC2
calcium channels, and NAADP mobilizes calcium
from intracellular stores [69]. Basile et al. recently
showed that CD38 and the other ADP ribosyl cyclases
also synthesize three novel adenine dinucleotides from
cADPR [70]. Pinpointing the role of these compounds
in intracellular calcium homeostasis is in the early
stages: Preliminary data indicate that they may play
relevant roles in the network of positive and negative
signals interchanged between cells expressing CD38 or
CD157 and interacting partners.
The ADP ribosyl cyclase family of enzymes is
present in a range of cells ranging from protists and
unicellular algae to higher Metazoa and Metaphyta.
Even if CD38 and CD157 share low sequence identi-
ties (õ30%), genetic analyses have shown that the
exon-intron structures of the two genes is remarkably
similar, suggesting that they evolved through gene
duplication phenomena from a common ancestor [71].
The similarities are maintained when comparing
CD38/CD157 with the Aplysia cyclase [72]. The
extracellular domain of CD38 was recently crystallized
and compared to the structures of CD157 and of the
Aplysia cyclase [73–76]. The results indicate that the
overall topology of the three enzymes is similar:
However, the large structural changes observed at the
two termini of the extracellular domains of CD38
434 Purinergic Signalling (2006) 2:431–441suggest that this gene underwent heavier evolutionary
stress than the CD157 and Aplysia ADP ribosyl
cyclase genes.
CD157
In contrast with CD38, CD157 is linked to the plasma
membrane by means of a glycosylphosphatidylinositol
(GPI) anchor. Another element distinguishing it from
CD38 concerns cell and tissue distribution, with
CD157 detected on human peripheral blood mono-
cytes, eosinophils, basophils, neutrophils and on the
majority of myeloperoxidase-positive bone marrow
(BM) myeloid precursors. Erythrocytes, platelets and
lymphoid cells from peripheral blood or from spleen
and tonsils, as well as lymphoblastoid cell lines of T
and B origin are negative [77]. Outside the immune
system, CD157 is expressed by the endothelium, by
synovial cells and derived lines and by follicular
dendritic cells [78], suggesting that CD38 and CD157
are mutually exclusive in terms of expression, with the
notable exception of the myeloid compartment.
The initial characterization of the structure and
distribution of CD157 was performed by Todd et al.,
using the Mo-5 mAb [77]. Later on, a contribution to
clustering as CD157 was independently provided by
the cloning of BST-1, a molecule expressed by BM
stromal cells and by similar lines derived from the
stroma of rheumatoid arthritis patients [22]. The
murine homologue of CD157 was cloned in the same
period by Dong et al. [79].
CD157 shares the same enzymatic properties as
CD38 and – as mentioned above – the two molecules
have a similar genetic organization and a close
chromosomal localization [23, 60, 80].
Again in analogy to CD38, CD157 acts as a receptor
capable of generating signals which can be measured in
terms of phosphorylation of a cascade of intracellular
proteins. The signals mediated by CD157 were initially
deﬁned and characterized in the context of the
interactions taking place between stromal and hemo-
poietic cells in closed environments, such as the BM or
the joints [22, 81]. The pathway induced upon CD157
cross-linking by a polyclonal antibody involved tyro-
sine phosphorylation of selected substrates in different
line models [82–84], amply reviewed in [85]. These
ﬁndings imply the existence of a cell bound ligand for
CD157, potentially alternative to NAD
+ and NADP
+,
as was the case for CD38. The existence of a ligand is
also supported by the ﬁnding that a soluble form of
CD157 binds to human B-cell, lines [78].
However, the pathway controlled by CD157, the
mechanisms of signal delivery, the molecular nature of
the substrates involved and the identiﬁcation of the
ligand/counter-receptor await further investigation.
Role of CD38 and CD157 in adhesion and migration
A signiﬁcant number of cell surface molecules in-
volved in the processes of cell adhesion and migration
have unexpectedly turned out to be enzymes [86]. A
role for CD38 in cell adhesion was initially hypothe-
sized more than a decade ago during analysis of the
dynamic adhesion phenomena taking place between T-
cell, if adjectival subsets and endothelial cells [87].
That work demonstrated involvement of CD38 in the
early phases of lymphocyte adhesion to the endothe-
lium [40] through direct interaction with CD31 [42].
CD38/CD31 interactions up-modulate integrin expres-
sion, thus promoting the ensuing phases in the
adhesion cascade, and induce the synthesis and secre-
tion of a panel of cytokines on T cells [88] and of
prostaglandin on endothelial cells [89], suggesting the
existence of a regulatory loop.
Another possibility is that these interactions depend
on modulation of the enzymatic activities of CD38.
This scenario seems likely in mice, where cADPR
catalyzed by CD38 is essential for eliciting a sustained
calcium response in murine neutrophils, triggering
chemotactic movements to infected tissues [90]. The
initial observation that CD38 KO mice are consider-
ably more sensitive to intratracheal infections with
culminated in the ﬁnding that the CD38 expressed by
murine neutrophils is a modulator of innate immune
responses to bacteria [91]. The effects mediated by
CD38 are directly dependent on calcium mobilization
regulated through cADPR production [91].
Transfer of these observations from mice to men has
only been partial. For one thing, CD38 is expressed at
minimal levels by normal human neutrophils, where, at
least in resting conditions, the dominant enzyme is
CD157. CD157 is a key molecule in the regulation of
polarization and migration of neutrophils in humans,
whereas the same has not been observed in mice.
Further, the mechanisms differ signiﬁcantly in that
they are apparently independent of the enzymatic
activity and rely mostly on localization in membrane
rafts and on physical interaction with b2 integrins [92].
A recent expansion of these ﬁndings to dendritic
cells adds to the list of differences between men and
mice. In both instances, CD38 is expressed by human
and murine mature dendritic cells and in both instan-
ces it controls migration and polarization of T cells
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dritic cells cADPR is the crucial second messenger
regulating dendritic cell functions [93], whereas these
events appear independent of cADPR production in
humans [49, 94].
Researchers are still grappling with the challenge of
devising a unifying view. One appealing possibility is
that CD38 and CD157 provide a connection between
calcium modulation via cADPR and classical signaling
cascades mediated by the tyrosine phosphorylation of
activating and inhibitory enzymes. The crystal struc-
ture of the molecules as well as biochemical evidence
indicate that they may work as dimers or dimers of
dimers [73, 95], creating a central cavity which could
operate as a channel for the internalization of the
enzymatic products. Following this hypothesis, the
NAD
+ and NADP
+ present in the extracellular space
would be trapped by CD38 and/or CD157 and the
cADPR produced immediately Fmicroinjected_ in the
cytoplasm, eventually binding ryanodine receptors and
inducing a calcium wave. This perturbation of calcium
homeostasis might be responsible for the activation of
calcium-dependent kinases, thus initiating a signaling
cascade closely resembling a canonical receptorial
pathway. CD31 and other putative ligands could act
as modulators of the three-dimensional structure of
CD38, modifying its propensity to bind the substrates
and start a signaling event. The localization of CD38
and CD157 in critical areas of the plasma membrane in
close association with signaling receptors would create
the necessary coupling of enzymatic and receptorial
machinery and would thus be a requisite for the signal
to begin.
CD38 and CD157 are part of a network of cell
surface enzymes
It seems that there is a natural blueprint linking CD38
and CD157 to other leukocyte ectoenzymes, which
share signaling abilities, enzymatic functions and
localization in specialized areas of the membrane.
Clustering enzyme/receptor molecules may serve as a
strategy for collecting precious elements from dead
cells, pooling together signaling receptors and adhe-
sion molecules, as well as generating products acting as
recruiters of different cells. A schematic representa-
tion of a virtual cell shows the mutual advantages that
encourage aggregation of the ectoenzymes (Fig. 1).
For instance, NAD
+ and ATP, intracellular metabo-
lites of energy metabolism, are candidates as signaling
molecules in extracellular environments [96, 97]. It is
hypothesized that high concentrations of NAD
+ and
ATP would be present at sites of cell necrosis and
tissue damage: When the compounds reach the extra-
cellular compartment, their levels are controlled by a
Fig. 1 Schematic representation of a virtual cell expressing a set of functionally related nucleotide-metabolizing cell surface enzymes.
These enzymes are involved in (i) scavenging of nucleotides freed in the extracellular environment during inﬂammatory processes; (ii)
modulation of purinergic receptor signaling and ART activity, and (iii) generation of immunomodulatory compounds, with extra- and
intra-cellular effects.
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demonstrated for CD39 and related ectonucleotidases
[98], which hydrolyze ATP to ADP and/or AMP.
Similarly, Koch-Nolte et al. recently reported that
CD38 enzymatically controls the availability of extra-
cellular NAD
+ as a substrate for ADP-ribosyltransfer-
ase (ART)-catalyzed ADP-ribosylation of cell surface
proteins [99].
Conclusions
The dual nature of CD38 can be formulated in terms
of its independent functions as receptor and as
enzyme, reﬂecting two separate strands in its long
evolutionary history. A reasonable alternative, which
ﬁnds itself the focus of intense but still unsuccessful
investigation, is that CD38 is a receptor that exploits
its enzymatic characteristics for signaling. These views
reﬂect – or, more appropriately, are biased by – the
points of view of the groups analyzing the molecules.
Immunologists tend to privilege the receptorial activ-
ities and the existence of a counter-receptor, fulﬁlling
the needs for being a genuine adhesion/homing
marker. Biochemists are attracted by the complexity
of the functions exerted by these multifunctional and
unique enzymes and their ability to regulate cytoplas-
mic calcium via an IP3-independent pathway.
Other controversies derive from the use of different
models, mainly man and mouse. Most of the experi-
ments on human samples have been performed on
leukocytes derived from blood, while the evidences in
murine and rat models are predominantly inferred
from cells derived from lymph nodes and spleen.
Nonetheless, we have also seen how the mouse system
beneﬁted from the existence of a CD38 KO model,
enabling an accurate and causative comparison with
the normal counterpart. The search for naturally
occurring CD38- individuals was attempted in humans
by analyzing more than 5,000 blood samples from
newborns, reproducing the experience gathered with
individuals lacking complement C2 and C4 [100]. In
the Italian sample analyzed, none of the newborns was
CD38j, suggesting that the absence of CD38 is
incompatible with life (F. Malavasi, unpublished
results). These results stand in apparent contradiction
to the mouse model, where the KO animal is
characterized by selected deﬁciencies in the immune
effectors and innate responses, but it is still able to live
and reproduce [90, 101]. The search for CD157
j
individuals (i.e., human KO) was pursued in a sample
of patients affected by paroxysmal nocturnal hemoglo-
binuria, a clonal disease characterized by the inability
to synthesize the GPI linkage. Indeed, these patients
are CD157
j in the pathological clone: However, this
approachisnot straightforward,fortheinabilityto form
GPI anchors is shared not only by CD157, but by all the
molecules with this linkage to the membrane [92].
What does seem evident, however, is that we are
faced with a family of molecules which descended
from the same distant ancestors, but which diverged
during evolution because of the pressures of natural
selection and the different needs of the organisms. The
cost of maintaining such systems must be counter-
balanced by a deﬁnite proﬁt for living systems.
Another hint favoring a common view comes from
analysis of the limited polymorphisms observed for the
genes of human CD38 [23]. Indeed, evaluation of the
allele distribution in a Caucasoid population reveals no
differences between individuals from continental Italy
and Sardinians, the latter considered the ancient core
of the genetic reservoir of Europeans and whose
unique characteristics have been conserved as a
consequence of geographic restraints [102]. These
Fig. 2 Schematic model representing a possible dual function for
CD38. Following this model, CD38 would perform as an
adhesion/homing receptor when surface expressed and as an
enzyme in the substrate-rich intracellular environments (cyto-
plasm and nucleus). The mechanisms exploited by CD38 to
translocate to and from the three compartments are currently
being analyzed.
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two alleles reaches far into the distant past. Future
research would beneﬁt from detailed study of the
differences between homozygous and heterozygous
individuals in terms of enzymatic functions and signal
transduction ability. The relationship between CD38
and selected diseases may also indicate that the mem-
bers of this ectoenzyme family played a role in the
defense against (or, better, resistance to) the diseases
that in more recent centuries modeled the genome that
we see today. Perhaps the greatest challenge to resolv-
ing these questions and controversies rests in deﬁning
the proper framework within which to interpret the
results achieved by the limited number of groups
working on ectoenzymes.
Another possibility awaiting conﬁrmation is that
CD38 may play a double function, according to its
localization (Fig. 2). Indeed, it may act as a receptor
when surface expressed and as an enzyme when inter-
nalized upon request or during its cytoplasmic transit
[103]. There is no current evidence that this model may
also hold true for CD157, mainly because of its GPI
anchor, nor has the role of soluble CD38 [104, 105] and
CD157 [106] been analyzed in any great detail.
The CD38 paradigm is also representative of a more
general pattern involving several nucleotide-metabo-
lizing ectoenzymes, such as CD39 [98] and CD26 [107].
Indeed, it appears that all these enzymes evolved from
very well conserved ancestors, usually acquiring a
membrane anchorage (either transmembrane or GPI)
and developing parallel and apparently independent
functions. Relevant in an immunological context is the
acquisition of functions classically associated with
receptor activity, such as signal transduction. These
include calcium mobilization and protein tyrosine
phosphorylation [108]. Another common trait is local-
ization in membrane lipid microdomains and physical
and functional association with partners specialized in
signal transduction [109, 110].
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